While Johnson & Johnson has been cleared to acquire Synthes, it must sell its wrist fractures unit, known as DVR, to Biomet. The FTC concluded, without this stipulation, Johnson & Johnson and Synthes would control 70 percent of the market for the wrist fracture treatment systems and harm competition.
Related Articles on Orthopedic Devices:
Mazor Launches C-Onsite Spinal Implant Verification Software on Global Scale
Premier Healthcare Alliance Announces New Agreements for Spinal Implants
Orthofix Resolves Alleged False Claims With $34M Settlement
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.